timothy sykes logo
TRVI Surges As Trevi Therapeutics Draws Aggressive Buyers Thumbnail
G Google News

TRVI Surges As Trevi Therapeutics Draws Aggressive Buyers

TIM SYKES•UPDATED JUL. 19, 2026, 10:08 AM ET
Reviewed by Bryce Tuoheyand Fact-checked by Matt Monaco

Trevi Therapeutics Inc. stocks have been trading up by 11.6 percent after promising clinical progress fueled strong investor optimism.

Market Insights For Active TRVI Traders

  • Shares jumped 10.9% to $19.25 in midday trading, flagging sharp momentum and strong demand.
  • The latest move shows a 10.4% gain, or $1.80, lifting the stock near recent highs.
  • Management is engaging institutional traders in a Cantor Fitzgerald non-deal roadshow in London on 2026/07/14, supporting growing interest.
  • Recent weekly candles show an explosive push from the mid-$17s to above $19, confirming breakout behavior.

Candlestick Chart

Weekly Update Jul 13 – Jul 17, 2026: On Sunday, July 19, 2026 Trevi Therapeutics Inc. stock [NASDAQ: TRVI] is trending up by 11.6%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Healthcare industry expert:

Analyst sentiment – positive

Trevi Therapeutics (TRVI) is a clinical‑stage biotech with no product revenue and a classic high‑risk, high‑reward profile. Fundamentals are loss‑making but capital position is strong: Q1 2026 operating loss was ~$14.9M and net loss ~$13.2M (‑$0.09/share), ROE and ROA are deeply negative (‑33% to ‑40% range). However, liquidity is exceptional with a current ratio of 24.8, no meaningful debt, and ~$172M in cash and short‑term investments, providing multi‑year runway at current burn.

Technically, the weekly tape shows a strong uptrend: closes stepped from $16.58 to $19.37, with higher highs and no downside follow‑through despite an intraday push above $18.50 midweek. The sharp move from $17.36 to $19.37 into week’s end, accompanied by elevated volume on 5‑minute candles, confirms aggressive accumulation. Key actionable level is $18.50: above it, momentum long setups remain valid; a sustained break below signals a likely consolidation toward $17.50.

Recent double‑digit price gains on July 17, driven by momentum and a Cantor‑hosted London NDR, underscore rising institutional interest despite no new clinical data. Versus broader Healthcare and Biotech benchmarks, TRVI trades as a high‑beta, catalyst‑driven name with superior balance‑sheet strength but binary pipeline risk. I expect continued outperformance into further investor outreach or data updates, with near‑term support at $18.00, major support at $16.50, and upside potential toward the $22–24 range.

More Breaking News

Quick Financial Overview

Trevi Therapeutics Inc. (TRVI) just printed a powerful upside extension, with shares pushing from around $17.36 to $19.37 over the recent week. Daily action shows a strong push where price spiked from the high-$17s to above $20 intraday before settling back near $19, which is typical of momentum names catching fast money. For short-term traders, that wide intraday range tells you liquidity and emotion are both elevated, which opens the door to both follow‑through and sharp reversals.

The 5‑minute tape shows a single, wide candle swinging between roughly $17.23 and $20.22 before closing near $19.07. That kind of range expansion usually marks a shift in who controls the stock, from slower hands to active traders. TRVI’s enterprise value is about $2.54B, with price to book near 10.3 and no meaningful earnings yet, which clearly frames this as a high‑expectation, development‑stage biotech story rather than a value play.

On the balance sheet, Trevi Therapeutics Inc. carries almost no debt, with total debt to equity at 0 and a current ratio of about 24.8, backed by roughly $171.8M in cash and short‑term investments. Operating cash flow in the latest quarter was about -$16.7M, free cash flow around -$16.8M, and net income at -$13.2M, so the company is still burning cash to fund research. Returns on assets and equity are deeply negative, which is normal for this phase but reminds traders that the story is binary around future data and milestones, not present profitability.

Conclusion

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”